Lineage Cell price target lowered to $2 from $3 at D. Boral Capital

D. Boral Capital lowered the firm’s price target on Lineage Cell Therapeutics (LCTX) to $2 from $3 and keeps a Buy rating on the shares. The firm cites dilution from the capital raise for the target cut.